Feel free to use our complete database with charts, tables and examples.
|Drug UPDATES: NUCALA ®- mepolizumab injection, powder
[Drug information / PDF] Click link for the latest monograph
Dosing: Click (+) next to Dosage and Administration section (drug info link)
Initial U.S. Approval: 2015
Mechanism of Action: Mepolizumab is an interleukin-5 antagonist (IgG1 kappa). IL-5 is the major cytokine responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils. Mepolizumab binds to IL-5 with a dissociation constant of 100 pM, inhibiting the bioactivity of IL-5 by blocking its binding to the alpha chain of the IL-5 receptor complex expressed on the eosinophil cell surface. Inflammation is an important component in the pathogenesis of asthma. Multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines) are involved in inflammation. Mepolizumab, by inhibiting IL-5 signaling, reduces the production and survival of eosinophils; however, the mechanism of mepolizumab action in asthma has not been definitively established.
INDICATIONS AND USAGE: NUCALA® is indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype. [See Clinical Studies (14).]
Limitations of Use
HOW SUPPLIED: For injection: 100 mg of lyophilized powder in a single-dose vial for reconstitution.
Drug UPDATES: CINQAIR ® (reslizumab) injection, for intravenous use
[Drug information / PDF]
Package insert - Dosing: Click (+) next to Dosage and Administration section (drug info link)
Anaphylaxis can be life-threatening. Patients should be observed for an appropriate period of time after CINQAIR administration by a healthcare professional prepared to manage anaphylaxis. Discontinue CINQAIR immediately if the patient experiences signs or symptoms of anaphylaxis
Initial U.S. Approval: 2016
Mechanism of Action:
INDICATIONS AND USAGE:
CINQAIR is an interleukin-5 antagonist monoclonal antibody (IgG4 kappa) indicated for add-on maintenance treatment of patients with severe asthma aged 18 years and older, and with an eosinophilic phenotype.
Limitations of Use: CINQAIR is not indicated for:
DOSAGE AND ADMINISTRATION
•CINQAIR is for intravenous infusion only. Do not administer as an intravenous push or bolus ( 2.1)
Discontinue the infusion immediately if the patient experiences a severe systemic reaction, including anaphylaxis
National Institutes of Health, U.S. National Library of Medicine, DailyMed Database.
Provides access to the latest drug monographs submitted to the Food and Drug Administration (FDA). Please review the latest applicable package insert for additional information and possible updates. A local search option of this data can be found here.